534 related articles for article (PubMed ID: 27486987)
1. Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Kang MG; Choi HW; Lee JH; Choi YJ; Choi HJ; Shin JH; Suh SP; Szardenings M; Kim HR; Shin MG
Oncotarget; 2016 Aug; 7(35):57036-57049. PubMed ID: 27486987
[TBL] [Abstract][Full Text] [Related]
2. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
3. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
[TBL] [Abstract][Full Text] [Related]
4. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
5. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
6. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
Gángó A; Mózes R; Boha Z; Kajtár B; Timár B; Király PA; Kiss R; Fésüs V; Nagy N; Demeter J; Körösmezey G; Borbényi Z; Marton I; Szőke A; Masszi T; Farkas P; Várkonyi J; Plander M; Pósfai É; Egyed M; Pál K; Radványi G; Hamed A; Csomor J; Matolcsy A; Alpár D; Bödör C
Leuk Res; 2018 Feb; 65():42-48. PubMed ID: 29306106
[TBL] [Abstract][Full Text] [Related]
8. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
9. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
[TBL] [Abstract][Full Text] [Related]
10. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
11. Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms.
Misawa K; Yasuda H; Araki M; Ochiai T; Morishita S; Shirane S; Edahiro Y; Gotoh A; Ohsaka A; Komatsu N
Int J Hematol; 2018 Jun; 107(6):673-680. PubMed ID: 29464483
[TBL] [Abstract][Full Text] [Related]
12. Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.
Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Pauwilai T; Singdong R; Rujirachaivej P; Chareonsirisuthigul T; Siriboonpiputtana T
Hematology; 2017 Dec; 22(10):599-606. PubMed ID: 28406068
[TBL] [Abstract][Full Text] [Related]
13. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.
Rumi E; Harutyunyan AS; Pietra D; Milosevic JD; Casetti IC; Bellini M; Them NC; Cavalloni C; Ferretti VV; Milanesi C; Berg T; Sant'Antonio E; Boveri E; Pascutto C; Astori C; Kralovics R; Cazzola M;
Blood; 2014 Apr; 123(15):2416-9. PubMed ID: 24553179
[TBL] [Abstract][Full Text] [Related]
14. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
Poluben LO; Neumerzhytska LV; Klymenko SV; Fraenkel P; Balk C; Shumeiko OO
Probl Radiac Med Radiobiol; 2020 Dec; 25():362-373. PubMed ID: 33361847
[TBL] [Abstract][Full Text] [Related]
15. Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Broséus J; Park JH; Carillo S; Hermouet S; Girodon F
Blood; 2014 Dec; 124(26):3964-6. PubMed ID: 25305205
[TBL] [Abstract][Full Text] [Related]
16. Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.
Park SH; Kim SY; Lee SM; Yi J; Kim IS; Kim HH; Chang CL; Lee EY; Song MK; Shin HJ; Chung JS
Ann Lab Med; 2015 Mar; 35(2):233-7. PubMed ID: 25729726
[TBL] [Abstract][Full Text] [Related]
17. Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms.
Trung NT; Quyen DT; Hoan NX; Giang DP; Trang TTH; Velavan TP; Bang MH; Song LH
BMC Med Genet; 2019 Jun; 20(1):115. PubMed ID: 31248375
[TBL] [Abstract][Full Text] [Related]
18. JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
Wang J; Zhang B; Chen B; Zhou RF; Zhang QG; Li J; Yang YG; Zhou M; Shao XY; Xu Y; Xu XH; Ouyang J; Xu J; Ye Q
Hematology; 2017 Apr; 22(3):145-148. PubMed ID: 27875935
[TBL] [Abstract][Full Text] [Related]
19. [The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
Lyu XD; Li YW; Guo Z; Xin YP; Hu JY; Fan RH; Song YP
Zhonghua Nei Ke Za Zhi; 2020 Jan; 59(1):35-39. PubMed ID: 31887834
[No Abstract] [Full Text] [Related]
20. JAK2, CALR, and MPL Mutation Profiles in Colombian patients with BCR-ABL Negative Myeloproliferative Neoplasms.
Giraldo-Rincón AI; Naranjo Molina S; Gomez-Lopera N; Aguirre Acevedo D; Ucroz Benavidez A; Gálvez Cárdenas K; Cuellar Ambrosí F; Torres JD; Ospina S; Palacio K; Gaviria Jaramillo L; Muñeton CM; Vasquez Palacio G
Colomb Med (Cali); 2023; 54(3):e2035353. PubMed ID: 38111518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
